文献速递肿瘤 PET/CT神经核医学

胰高血糖素样肽-1受体(GLP-1R)PET/CT、SPECT/CT与3T MRI定位隐匿性胰岛素瘤的诊断准确性比较:前瞻性交叉影像研究

Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-07-28

研究前瞻性纳入52例内源性高胰岛素性低血糖(EHH)成人患者,随机交叉顺序行68Ga-DOTA-exendin-4 GLP-1R PET/CT、111In-DOTA-exendin-4 SPECT/CT与研究MRI,以手术病理及治疗结局为参考标准。38例有确定性病理结果者中,PET/CT准确性93.9%(87.8-97.5%),高于SPECT/CT的67.5%与研究MRI的67.6%,后两者间P=1.0。作者认为PET/CT定位良性胰岛素瘤显著优于SPECT/CT和MRI,CT/MRI定位失败的患者应考虑使用。

要点

  • 38例最终分析中,GLP-1R PET/CT准确性93.9%,SPECT/CT 67.5%,研究MRI 67.6%。
  • SPECT/CT与研究MRI准确性比较P=1.0,无显著差异。
  • PET/CT对临床管理影响42.3%,SPECT/CT 32.7%,研究MRI 33.3%。

核心结论

  • 68Ga-DOTA-exendin-4 PET/CT定位良性胰岛素瘤显著优于111In-DOTA-exendin-4 SPECT/CT和MRI。
  • 作者建议CT/MRI定位失败的患者应考虑使用68Ga-DOTA-exendin-4 PET/CT。

研究设计与样本

  • 前瞻性交叉影像研究,纳入因EHH出现神经低血糖症状的成人患者,从2014年1月至2017年3月共招募52例。
  • GLP-1R PET/CT、SPECT/CT与研究MRI在3-4天内按随机交叉顺序完成,参考标准为手术病理及治疗结局。

主要发现

  • 招募前所有影像及侵入性检查在46.2%的患者中识别出可疑病灶。
  • GLP-1R PET/CT、SPECT/CT和研究MRI分别在78.8%、63.5%和63.4%的患者中检出可疑病灶。
  • 38例有确定性病理结果者中,PET/CT、SPECT/CT、研究MRI和既往外部CT/MRI的准确性分别为93.9%(87.8-97.5%)、67.5%(58.1-76.0%)、67.6%(58.0-76.1%)和40.0%(23.9-57.9%)。
  • 上述准确性比较除SPECT/CT与研究MRI比较P=1.0外,其余P值均<0.01。
  • PET/CT、SPECT/CT和研究MRI对临床管理的影响分别为42.3%、32.7%和33.3%,阅片一致率分别为89.5%、75.7%和71.1%。

临床怎么用

  • 作者建议在CT/MRI定位失败的患者中考虑使用68Ga-DOTA-exendin-4 PET/CT定位良性胰岛素瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults, and because of their small size are difficult to localise. The purpose of the study was to test the diagnostic accuracy and clinical impact of glucagon-like peptide-1 receptor (GLP-1R) PET/CT using 68Ga-DOTA-exendin-4 in consecutive adult patients referred for localisation of insulinomas. The results were compared with 111In-DOTA-exendin-4 SPECT/CT, study-MRI and previously performed external CT and/or MRI (prior external CT/MRI). METHODS: We prospectively enrolled patients with neuroglycopenic symptoms due to EHH. GLP-1R PET/CT, SPECT/CT and study-MRI were performed in a randomised, crossover order within 3-4 days. The reference standard was surgery with histology and treatment outcome. RESULTS: From January 2014 until March 2017, 52 patients were recruited. All imaging and invasive procedures before recruitment identified suspicious lesions in 46.2% of patients. GLP-1R PET/CT, SPECT/CT and study-MRI detected suspicious lesions in 78.8%, 63.5% and 63.4% of patients, respectively. In 38 patients, conclusive histology was available for final analysis. Accuracy (95% confidence interval) for PET/CT, SPECT/CT, study-MRI and prior external CT/MRI was 93.9% (87.8-97.5%), 67.5% (58.1-76.0%), 67.6% (58.0-76.1%) and 40.0% (23.9-57.9%), respectively (all P values < 0.01, except comparison of SPECT/CT and study-MRI with a P value = 1.0). Impact on clinical management was 42.3%, 32.7% and 33.3% for PET/CT, SPECT/CT and study-MRI, respectively. Percentage reading agreement was 89.5%, 75.7%, and 71.1% for PET/CT, SPECT/CT and study-MRI, respectively. CONCLUSION: 68Ga-DOTA-exendin-4 PET/CT performed significantly better than 111In-DOTA-exendin-4 SPECT/CT and MRI in the localisation of benign insulinomas and should be considered in patients where localisation fails with CT/MRI ( ClinicalTrials.gov , NCT02127541).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Antwi K, Fani M, Heye T, et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur J Nucl Med Mol Imaging. 2018. PMID: 30054698. doi:10.1007/s00259-018-4101-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。